Table 5.

The HR of etiology in the studies

Authors (year)	Study design	Aetiology	Endpoint	HR
Kudo et al. (2011) [15]	RCT trial	HBV = 20%	TTP	0.81(0.62–1.07)
		HCV = 60%
Bai et al. (2013) [46]	Comparative study	HBV = 87.9%	OS	1.01(0.60–1.71)
		HCV = 4.9%
Muhammad et al. (2013) [47]	Comparative study	ST:HCV = 69%	OS	1.04(0.66–1.63)
		DT:HCV = 93%
Zhao et al. (2013) [41]	Non-comparative study	HBV = 80%	OS	1.372(0.773–2.437)
		HCV = 5%
Hu et al. (2014) [14]	Comparative study	ST:B = 82.9%	TTP	1.01(0.76–1.34)
		T:B = 79.8%
Yao et al. (2016) [12]	Comparative study	ST:HBV = 84%	OS	1.228(0.593–2.540)
		T:HBV = 83%	TTP	0.878(0.494–1.561)

Abbreviations: HR hazard ratio, OS overall survival, TTP time to progression, RCT randomized controlled trials, ST sorafenib plus TACE, DT DEB –TACE